A model to evaluate mass vaccination against pneumococcus as a countermeasure against pandemic influenza

Vaccine

Volumn 29, Issue 31, 2011, Pages 5065-5077

  Crowe, Sonya ^a   Utley, Martin ^a   Walker, Guy ^b   Grove, Peter ^b   Pagel, Christina ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b Department of Health ^*  (United Kingdom)

Author keywords

Mathematical model; Pandemic influenza; Pneumococcal disease; Vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CONTROLLED STUDY; DECISION MAKING; HOSPITAL ADMISSION; INFECTION RISK; MASS IMMUNIZATION; MATHEMATICAL MODEL; MORTALITY; PANDEMIC INFLUENZA; PNEUMOCOCCAL INFECTION; PREVENTIVE MEDICINE; PRIORITY JOURNAL; UNITED KINGDOM; VACCINATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; FEMALE; GREAT BRITAIN; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA, HUMAN; MALE; MASS VACCINATION; MIDDLE AGED; MODELS, THEORETICAL; PANDEMICS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; YOUNG ADULT;

EID: 79959741707     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.04.034     Document Type: Article

References (40)

1. Civil Contingencies Secretariat Overarching government strategy to respond to pandemic influenza analysis of the scientific evidence base 2007, Cabinet Office.
2. UK Department of Health Pandemic flu-a national framework for responding to an influenza pandemic 2007.
3. Morens D.M., Fauci A.S. The 1918 influenza pandemic: insights for the 21st century. Journal of Infectious Diseases 2007, 195(7):1018-1028.
4. Taubenberger J.K., Morens D.M. 1918 influenza: the mother of all pandemics. Emerging Infectious Diseases 2006, 12(1):15-22.
5. Nguyen-Van-Tam J.S., Hampson A.W. The epidemiology and clinical impact of pandemic influenza. Vaccine 2003, 21(16):1762-1768.
6. Cox N.J., Tamblyn S.E., Tam T. Influenza pandemic planning. Vaccine 2003, 21(16):1801-1803.
7. Bautista E., Chorpitayasunondh T., Gao Z.C., Harper S.A., Shaw M., Uyeki T.M., et al. Medical progress: clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. New England Journal of Medicine 2010, 362(18):1708-1719.
8. Donaldson L.J., Rutter P.D., Ellis B.M., Greaves F.E.C., Mytton O.T., Pebody R.G., et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. British Medical Journal 2009, 339:b5213.
9. Hament J.M., Kimpen J.L.L., Fleer A., Wolfs T.F.W. Respiratory viral infection predisposing for bacterial disease: a concise review. FEMS Immunology and Medical Microbiology 1999, 26(3-4):189-195.
10. Peltola V.T., McCullers J.A. Respiratory viruses predisposing to bacterial infections: role of neuraminidase. Pediatric Infectious Disease Journal 2004, 23(1):S87-S96.
11. Klugman K.P., Chien Y.W., Madhi S.A. Pneumococcal pneumonia and influenza: a deadly combination. Vaccine 2009, 27:C9-C14.
12. Morens D.M., Taubenberger J.K., Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. Journal of Infectious Diseases 2008, 198(7):962-970.
13. Madhi S.A., Klugman K.P. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nature Medicine 2004, 10(8):811-813.
14. Chien Y.W., Klugman K.P., Morens D.M. Bacterial pathogens and death during the 1918 influenza pandemic. New England Journal of Medicine 2009, 361(26):2582-2583.
15. Brundage J.F. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infectious Diseases 2006, 6(5):303-312.
16. Memoli M.J., Morens D.M., Taubenberger J.K. Pandemic and seasonal influenza: therapeutic challenges. Drug Discovery Today 2008, 13(13-14):590-595.
17. Smith K.J., Raymund M., Nowalk M.P., Roberts M.S., Zimmerman R.K. Cost-effectiveness of pneumococcal polysaccharide vaccine among healthcare workers during an influenza pandemic. American Journal of Managed Care 2010, 16(3):200-206.
18. Moore ML. Use of PPSV23 for prevention of pneumococcal pneumonia during an influenza pandemic. Summary report of the Advisory Committee of Immunization Practices 2009, Centres for Disease Control and Prevention, [accessed 24.02.11]. http://www.cdc.gov/vaccines/recs/acip/downloads/min-archive/min-feb09.rtf.
19. Scientific Pandemic Influenza Advisory Committee (SPI) Subgroup on Modelling Modelling summary: advised planning assumptions 2008, [accessed 24.02.11]. http://www.advisorybodies.doh.gov.uk/spi/minutes/spi-m-modellingsummary.pdf.
20. Scientific Pandemic Influenza Advisory Committee (SPI): Subgroup on Modelling. Modelling summary (Interim version 2.7); 2010 (unpublished).
21. UK Department of Health Chapter 25: Pneumococcal. Immunisation against infectious disease-'The Green Book' 2010, [accessed 24.02.11]. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_079917.
22. Office for National Statistics 2008-based National Population Projections 2009, [accessed 24.02.11]. http://www.statistics.gov.uk/pdfdir/pproj1009.pdf.
23. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part I. Efficacy of PPV in the elderly: a comparison of meta-analyses. European Journal of Epidemiology 2004, 19(4):353-363.
24. Moberley S.A., Holden J., Tatham D.P., Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database of Systematic Reviews 2008, 1:CD000422. 10.1002/14651858.CD000422.pub2.
25. Rothberg M.B., Haessler S.D. Complications of seasonal and pandemic influenza. Critical Care Medicine 2010, 38(4):91-97.
26. European Centre for Disease Prevention and Control. Health information report: pandemic (H1N1) 2009 planning assumptions to end of May 2010 for EU/EEA countries 2009, [accessed 24.02.11]. http://www.ecdc.europa.eu/en/healthtopics/Documents/091111_Pandemic_(H1N1)_2009_Planning_Assumptions_for_EU_EEA_countries.pdf.
27. Centres for Disease Control and Prevention Morbidity and Mortality Weekly Report 2009, 58:941-947.
28. Chief Medical Officer Fortnightly bulletin 2010 2010, [accessed 24.02.11]. http://www.dh.gov.uk/dr_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_112079.pdf.
29. WHO position statement on pneumococcal vaccines. Weekly Epidemiological Record 1999, 74:177-184.
30. UK Department of Health Analytical Team. Cost benefit analysis of vaccination against pneumococcus as a countermeasure against the next influenza pandemic (private communication); 2010.
31. Fedson D.S., Liss C. Precise answers to the wrong question: prospective clinical trials and the meta-analyses of pneumococcal vaccine in elderly and high-risk adults. Vaccine 2004, 22(8):927-946.
32. Honkanen P.O., Keistinen T., Miettinen L., Herva E., Sankilampi U., Laara E., et al. Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older. Vaccine 1999, 17(20-21):2493-2500.
33. Cornu C., Yzebe D., Leophonte P., Gaillat J., Boissel J.P., Cucherat M. Efficacy of pneumococcal polysaccharide vaccine in immunocompetent adults: a meta-analysis of randomized trials. Vaccine 2001, 19(32):4780-4790.
34. Conaty S., Watson L., Dinnes J., Waugh N. The effectiveness of pneumococcal polysaccharide vaccines in adults: a systematic review of observational studies and comparison with results from randomised controlled trials. Vaccine 2004, 22(23-24):3214-3224.
35. Jackson L.A., Neuzil K.M., Yu O.C., Benson P., Barlow W.E., Adams A.L., et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. New England Journal of Medicine 2003, 348(18):1747-1755.
36. Centres for Disease Control and Prevention Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices. Morbidity and Mortality Weekly Report 1997, 46(RR-08):1-24.
37. Melegaro A., Edmunds W.J. The 23-valent pneumococcal polysaccharide vaccine. Part II. A cost-effectiveness analysis for invasive disease in the elderly in England and Wales. European Journal of Epidemiology 2004, 19(4):365-375.
38. Health Protection Agency Health Protection Agency welcomes addition of new pneumococcal vaccine to childhood immunisation programme 2010, [accessed 24.02.11]. http://www.hpa.org.uk/NewsCentre/NationalPressReleases/2010PressReleases/100119HealthProtectionAgencywelcomesadditionofnewpn/.
39. Pebody M. Autonomous underwater vehicle collision avoidance for under-ice exploration. Journal of Engineering for the Maritime Environment 2008, 222(M2):53-66.
40. Begum F., Pebody R.G. The annual PPV uptake report in 65 years old and over for England. Report commissioned by the Department of Health and written by the Health Protection Agency 2008.